Rijksinstituut voor VolksgezondheidAn early dialogue between nanomedicine developers and regulatory authorities are of utmost importance to anticipate quality and safety requirements for these innovative health products. In order to stimulate interactions between the various communities involved in a translation of nanomedicines to clinical applications, the European Commission's Joint Research Centre hosted a workshop titled “Bridging communities in the field of Nanomedicine” in Ispra/Italy on the 27th −28th September 2017. Experts from regulatory bodies, research institutions and industry came together to discuss the next generation of nanomedicines and their needs to obtain regulatory approval. The workshop participants came up with recommendations highlighting methodological gaps that should be addressed in ongoing projects addressing the regulatory science of nanomedicines. In addition, individual opinions of experts relevant to progress of the regulatory science in the field of nanomedicine were summarised in the format of a survey.
Met nanotechnologie en andere technieken kunnen materialen ontwikkeld worden met veelbelovende eigenschappen. Deze materialen kunnen een belangrijke bijdrage leveren aan nieuwe medicijnen of aan maatschappelijke uitdagingen zoals de energietransitie. Het is belangrijk dat deze nieuwe materialen veilig zijn voor mens en milieu en duurzaam. Daarom onderzoekt het RIVM deze ontwikkelingen.
Nanotechnology and other techniques can be used to create materials with promising properties. These materials could significantly contribute to the development of new medicines and tackle societal challenges such as the energy transition. It is important that these new materials are safe for humans and the environment, as well as sustainable. For this reason, RIVM investigates these developments.